232 related articles for article (PubMed ID: 30310468)
1. Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Watanabe H
Eur Cardiol; 2018 Aug; 13(1):35-37. PubMed ID: 30310468
[TBL] [Abstract][Full Text] [Related]
2. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
[TBL] [Abstract][Full Text] [Related]
3. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
4. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
5. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
6. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
[TBL] [Abstract][Full Text] [Related]
7. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Gratsianskaya SE; Valieva ZS; Martynyuk TV
Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
[TBL] [Abstract][Full Text] [Related]
8. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
9. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
10. Riociguat for the treatment of pulmonary hypertension.
Hambly N; Granton J
Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
[TBL] [Abstract][Full Text] [Related]
11. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G
Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687
[TBL] [Abstract][Full Text] [Related]
12. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Mielniczuk LM; Swiston JR; Mehta S
Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
[TBL] [Abstract][Full Text] [Related]
13. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
[TBL] [Abstract][Full Text] [Related]
14. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Koress C; Swan K; Kadowitz P
Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
[TBL] [Abstract][Full Text] [Related]
15. A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway.
Beghetti M; Gorenflo M; Ivy DD; Moledina S; Bonnet D
Pediatr Pulmonol; 2019 Oct; 54(10):1516-1526. PubMed ID: 31313530
[TBL] [Abstract][Full Text] [Related]
17. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
18. Modern view on the place of riociguat in the treatment of pulmonary hypertension.
Valieva ZS; Taran IN; Martynyuk TV; Chazova IY
Ter Arkh; 2018 Apr; 90(4):55-59. PubMed ID: 30701875
[TBL] [Abstract][Full Text] [Related]
19. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
20. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Schermuly RT; Stasch JP; Pullamsetti SS; Middendorff R; Müller D; Schlüter KD; Dingendorf A; Hackemack S; Kolosionek E; Kaulen C; Dumitrascu R; Weissmann N; Mittendorf J; Klepetko W; Seeger W; Ghofrani HA; Grimminger F
Eur Respir J; 2008 Oct; 32(4):881-91. PubMed ID: 18550612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
